These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32447327)

  • 41. Understanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence.
    Nivean PD; Madhivanan N; Kumaramanikavel G; Berendschot TTJM; Webers CAB; Paridaens D
    Hormones (Athens); 2024 Mar; 23(1):25-34. PubMed ID: 37910311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological treatments for thyroid eye disease.
    Modjtahedi SP; Modjtahedi BS; Mansury AM; Selva D; Douglas RS; Goldberg RA; Leibovitch I
    Drugs; 2006; 66(13):1685-700. PubMed ID: 16978034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit.
    Mellington FE; Dayan CM; Dickinson AJ; Hickey JL; MacEwen CJ; McLaren J; Perros P; Rose GE; Uddin J; Vaidya B; Foley P; Lazarus JH; Mitchell A; Ezra DG;
    Orbit; 2017 Jun; 36(3):159-169. PubMed ID: 28296512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phenotypes of Thyroid Eye Disease.
    Uddin JM; Rubinstein T; Hamed-Azzam S
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S28-S33. PubMed ID: 29905636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on the clinical assessment and management of thyroid eye disease.
    Roos JCP; Murthy R
    Curr Opin Ophthalmol; 2019 Sep; 30(5):401-406. PubMed ID: 31313753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thyroid eye disease: therapy in the active phase.
    Bhatti MT; Dutton JJ
    J Neuroophthalmol; 2014 Jun; 34(2):186-97. PubMed ID: 24821102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.
    Banga JP; Nielsen CH; Gilbert JA; El Fassi D; Hegedus L
    Thyroid; 2008 Sep; 18(9):973-81. PubMed ID: 18752425
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The changing landscape of thyroid eye disease: current clinical advances and future outlook.
    Moledina M; Damato EM; Lee V
    Eye (Lond); 2024 Jun; 38(8):1425-1437. PubMed ID: 38374366
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thyroid eye disease: current and potential medical management.
    Pouso-Diz JM; Abalo-Lojo JM; Gonzalez F
    Int Ophthalmol; 2020 Apr; 40(4):1035-1048. PubMed ID: 31919775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment modalities of thyroid related orbitopathy.
    Ahn ES; Subramanian PS
    Indian J Ophthalmol; 2014 Oct; 62(10):999-1002. PubMed ID: 25449934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thyroid eye disease: From pathogenesis to targeted therapies.
    Yoon JS; Kikkawa DO
    Taiwan J Ophthalmol; 2022; 12(1):3-11. PubMed ID: 35399971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thyroid eye disease: what is new to know?
    Li Z; Cestari DM; Fortin E
    Curr Opin Ophthalmol; 2018 Nov; 29(6):528-534. PubMed ID: 30124533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cigarette smoking and thyroid eye disease: a systematic review.
    Thornton J; Kelly SP; Harrison RA; Edwards R
    Eye (Lond); 2007 Sep; 21(9):1135-45. PubMed ID: 16980921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changing trend in referral to secondary care specialist thyroid eye disease clinic following the Amsterdam declaration.
    Quinn AS; Dujardin LR; Knight B; Benzimra J; Quinn AG; Vaidya B
    Int Ophthalmol; 2018 Feb; 38(1):301-306. PubMed ID: 28181061
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential utility of rituximab for Graves' orbitopathy.
    Salvi M; Vannucchi G; Beck-Peccoz P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
    Teo HM; Smith TJ; Joseph SS
    Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hyperthyroid vs hypothyroid eye disease: the same severity and activity.
    Kashkouli MB; Pakdel F; Kiavash V; Heidari I; Heirati A; Jam S
    Eye (Lond); 2011 Nov; 25(11):1442-6. PubMed ID: 21818129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.